| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $19,999,990 | 1 | 33 |
Sells | $315,796 | 2 | 67 |
| Fairmount Funds Management LLC | 1 | $20M | 0 | $0 | $20M | |
| Tousignant Jennifer | Chief Legal Officer | 0 | $0 | 2 | $315,796 | $-315,796 |
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, …
Over the last 12 months, insiders at Viridian Therapeutics, Inc. have bought $20M and sold $315,796 worth of Viridian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viridian Therapeutics, Inc. have bought $17.72M and sold $3.06M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC () — $20M.
The last purchase of 1,176,470 shares for transaction amount of $20M was made by Fairmount Funds Management LLC () on 2026‑05‑11.
| 2026-08-19 | Sale | Tousignant Jennifer | Chief Legal Officer | 10,000 0.0087% | $24.50 | $245,000 | -10.12% | |
| 2026-05-11 | Fairmount Funds Management LLC | 1.18M 1.3704% | $17.00 | $20M | +13.58% | |||
| 2025-12-31 | Sale | Tousignant Jennifer | Chief Legal Officer | 2,272 0.0028% | $31.16 | $70,796 | -33.03% | |
| 2024-09-27 | Mahoney Stephen F. | President and CEO | 21,400 0.0284% | $23.33 | $499,262 | -24.90% | ||
| 2024-09-27 | Beetham Thomas W. | Chief Operating Officer | 5,000 0.0066% | $23.41 | $117,050 | -24.90% | ||
| 2024-09-13 | Fairmount Funds Management LLC | 1.6M 2.1285% | $18.75 | $30M | -20.58% | |||
| 2024-01-22 | Fairmount Funds Management LLC | See Remarks | 476,190 0.9578% | $21.00 | $10M | -11.30% | ||
| 2023-06-16 | Sale | Meisner Lara | Chief Legal Officer | 27 <0.0001% | $28.35 | $765 | -34.59% | |
| 2023-06-15 | Sale | Meisner Lara | Chief Legal Officer | 2,269 0.0054% | $28.02 | $63,577 | -36.35% | |
| 2023-06-06 | Sale | Meisner Lara | Chief Legal Officer | 5,126 0.0121% | $25.02 | $128,253 | -28.07% | |
| 2023-06-05 | Sale | Meisner Lara | Chief Legal Officer | 499 0.0012% | $25.03 | $12,490 | -27.62% | |
| 2023-06-02 | Sale | Meisner Lara | Chief Legal Officer | 1,875 0.0044% | $24.21 | $45,394 | -25.76% | |
| 2023-04-12 | Myers Scott Dunseth | Chief Executive Officer | 4,000 0.01% | $25.37 | $101,479 | -24.18% | ||
| 2023-03-13 | Myers Scott Dunseth | 5,500 0.0137% | $29.15 | $160,324 | -32.01% | |||
| 2023-03-09 | Sale | Meisner Lara | General Counsel and Secretary | 29,971 0.0733% | $29.07 | $871,257 | -33.06% | |
| 2023-02-02 | Sale | Violin Jonathan | Chief Executive Officer | 50,000 0.1224% | $36.80 | $1.84M | -41.33% | |
| 2023-01-23 | Sale | Meisner Lara | General Counsel and Secretary | 6,843 0.0169% | $35.66 | $244,021 | -37.40% | |
| 2023-01-17 | Sale | Katz Barrett | Chief Medical Officer | 24,853 0.0607% | $37.21 | $924,780 | -40.15% | |
| 2023-01-10 | Sale | Katz Barrett | Chief Medical Officer | 47,377 0.1162% | $35.30 | $1.67M | -35.58% | |
| 2022-12-21 | Sale | Meisner Lara | General Counsel and Secretary | 16,326 0.0503% | $29.19 | $476,556 | -19.67% |
| Fairmount Funds Management LLC | 5090928 4.4936% | $128.04M | 4 | 0 | +3.78% | |
| Frazier Life Sciences Public Fund, L.P. | 10 percent owner | 1505200 1.3286% | $37.86M | 1 | 0 | +25.75% |
| Fairmount Healthcare Fund II L.P. | 1363764 1.2038% | $34.3M | 1 | 0 | +8.69% | |
| Booth Bruce | director | 1351090 1.1926% | $33.98M | 1 | 0 | +6.91% |
| Logos Global Master Fund LP | 10 percent owner | 550000 0.4855% | $13.83M | 2 | 0 | +5.96% |
| Riccitelli Samuel D | President & CEO | 345130 0.3046% | $8.68M | 2 | 0 | |
| Myers Scott Dunseth | Chief Executive Officer | 259500 0.2291% | $6.53M | 2 | 0 | <0.0001% |
| Mahoney Stephen F. | President and CEO | 21400 0.0189% | $538,210.00 | 1 | 0 | <0.0001% |
| Hughes Thomas E. | director | 12827 0.0113% | $322,599.05 | 1 | 1 | <0.0001% |
| Levy Adam Scott | Chief Business Officer | 10540 0.0093% | $265,081.00 | 2 | 0 | +4.18% |
| Beetham Thomas W. | Chief Operating Officer | 6000 0.0053% | $150,900.00 | 1 | 0 | <0.0001% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$28,907,358 | 35 | 41.41% | $2.28B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$1,603,489 | 30 | 98.90% | $2.33B |
| Increased Positions | 161 | +104.55% | 33M | +34.88% |
| Decreased Positions | 66 | -42.86% | 19M | -19.97% |
| New Positions | 77 | New | 14M | New |
| Sold Out Positions | 19 | Sold Out | 7M | Sold Out |
| Total Postitions | 249 | +61.69% | 108M | +14.91% |
| Fmr Llc | $375,810.00 | 12.89% | 12.25M | +10,552 | +0.09% | 2025-09-30 |
| Blackrock, Inc. | $166,547.00 | 5.71% | 5.43M | -92,514 | -1.68% | 2025-09-30 |
| Deep Track Capital, Lp | $165,072.00 | 5.66% | 5.38M | 0 | 0% | 2025-09-30 |
| Kynam Capital Management, Lp | $135,849.00 | 4.66% | 4.43M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $132,905.00 | 4.56% | 4.33M | -176,525 | -3.92% | 2025-09-30 |
| Vr Adviser, Llc | $119,122.00 | 4.09% | 3.88M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $106,150.00 | 3.64% | 3.46M | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $98,176.00 | 3.37% | 3.2M | -2M | -34.36% | 2025-09-30 |
| Tang Capital Management Llc | $87,221.00 | 2.99% | 2.84M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $80,055.00 | 2.75% | 2.61M | -132,223 | -4.82% | 2025-09-30 |